At AAD 2025, UCB presented long-term data from the BE BRIGHT extension trial showing that 67.7% of patients with moderate-to-severe psoriasis treated with Bimzelx (bimekizumab) maintained complete skin clearance (PASI 100) through five years. The majority of patients remained on therapy, and discontinuation due to adverse events was under 5%. These results are among the longest available for IL-17 inhibitors and highlight the durability of dual IL-17A/F blockade. Improvements were consistent across BMI groups and comorbidity profiles. Patient-reported quality-of-life metrics improved in tandem with skin outcomes. No new safety signals were reported, supporting Bimzelx's long-term tolerability. As dermatologists and payers prioritize treatments with sustained outcomes and minimal burdens, Bimzelx is increasingly positioned as a preferred IL-17 option.

Citation: https://www.biospace.com/article/releases/ucb-presents-five-year-data-on-bimzelx-at-aad-2025/

Implication: These results reinforce Bimzelx as a long-term solution in plaque psoriasis.